PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals is a drug company developing cancer treatments that target a specific genetic mutation called p53 Y220C. Their main experimental drug, rezatapopt, is currently in Phase 2 clinical trials, which is the middle stage of testing before drugs can be approved for patient use. The company focuses on precision oncology, meaning they design drugs for patients whose cancers have particular genetic characteristics rather than one-size-fits-all treatments. The company is based in Princeton, New Jersey.